The Lancet Global Health
-
1
[Articles] Global inequalities in cardiometabolic care and achievable cardiovascular risk reduction by wealth, region, and sex: a pooled analysis of individual participant data from 76 countries
-
2
[Correspondence] Why the health community should care about the next UN Secretary-General
-
3
[Articles] External validation of a treatment decision algorithm for tuberculosis in children living with HIV: a diagnostic cohort study
-
4
[Viewpoint] Beyond monitoring misery during conflict: the political economy of global health reform
-
5
[Articles] Hypoxaemia and mortality in children with lower respiratory infection in low-income and middle-income countries: systematic review and meta-analysis
-
6
[Correspondence] Beyond the metrification of diversity: compositional and relational equity in global health representation
-
7
[Comment] Embedding social and behavioural science across and beyond Ebola clinical trials: a critical research priority
-
8
[Comment] Economic case for universal hepatitis B birth dose vaccination in South Africa
-
9
[Articles] Cost-effectiveness of the hepatitis B birth-dose vaccine in South Africa: a mathematical modelling analysis
-
10
[Comment] From commitment to governance: what should the 2026 UN high-level meeting on pandemic preparedness deliver?
The Lancet Healthy Longevity
-
1
[Feature] Highlights of AAIC 2026
-
2
[Comment] The frailty–influenza paradox: enhanced risk of severe infection, yet greater high-dose vaccine effectiveness
-
3
[Articles] Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2
-
4
[Comment] Climate change and medication safety in older adults: an overlooked priority for healthy ageing
-
5
[Comment] Addressing the needs of older people in Venezuela: beyond the earthquakes and humanitarian health crisis
-
6
[Articles] Supervised multimodal prehabilitation of older patients with frailty or prefrailty before elective surgery: a multicentre randomised controlled outcome assessor-blinded trial
-
7
[Editorial] Ageing Well for Indigenous Peoples: Closing the Health Equity Gap
-
8
[Review] Effectiveness of digital health technologies for post-discharge follow-up and management in older adults: a systematic review
-
9
[Comment] Mode of anaesthesia for hip fracture surgery: is it time to put the question to sleep?
-
10
[Articles] Spinal versus general anaesthesia and serious complications in older patients undergoing hip fracture surgery in Germany: a multicentre randomised clinical trial
The Lancet HIV
-
1
[Review] Metabolic dysfunction-associated steatotic liver disease in people living with HIV: a framework for integrated screening and care
-
2
[Comment] Advancing a fixed-dose combination for children with HIV
-
3
[Articles] Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antivir
-
4
[Articles] Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa
-
5
[Comment] Low-level viraemia in children living with HIV
-
6
[Comment] Social sciences at the centre of HIV stigma reduction
-
7
[Articles] Targeted point-of-care HIV testing at birth for newborns at high risk of vertical transmission in Botswana: a prospective cohort study
-
8
[Culture] Prejudice still flickering away
-
9
[Profile] Taking HIV outreach from the streets to the apps in Morocco
-
10
[Review] Epidemiology and management of HIV-2
The Lancet Infectious Diseases
-
1
[Correspondence] Pragmatic tuberculosis trials must measure what determines implementation
-
2
[Comment] South Sudan's first 100 days of Bundibugyo Ebola readiness
-
3
[Personal View] Is a tiered classification framework needed for sexually transmitted infections?
-
4
[Articles] Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial
-
5
[Comment] Developing a better flu vaccine
-
6
[Comment] Recalibrating quantitative PCR cycle-thresholds could improve mpox diagnostic accuracy in high-transmission settings
-
7
[Articles] The risk of mpox false positive results in high transmission settings: evidence from a multi-site observational study in DR Congo
-
8
[Review] Nucleic acid amplification testing and genome sequencing for WHO priority viruses in Africa: a scoping review
-
9
[Corrections] Correction to Lancet Infect Dis 2026; 26: 832–42
-
10
[Articles] Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Neurology
-
1
[Review] The role of lifestyle interventions in symptom management and disease modification in Parkinson's disease
-
2
[Comment] Advances in understanding sudden unexpected death in people with drug-resistant epilepsy
-
3
[Articles] Seizure-related biomarkers of sudden unexpected death in epilepsy (SUDEP) in drug-resistant focal epilepsy (REPO2MSE): a prospective, multicentre case–control study
The Lancet Microbe
-
1
[Articles] Bacterial co-detection in individuals with acute respiratory infections through a direct-to-consumer platform in China: a retrospective cross-sectional study
-
2
[Correspondence] Antimicrobial resistance in community-acquired lower respiratory tract infection: interpretation matters
-
3
[Correspondence] Prevalence-adaptive sequential antigen and molecular testing for mpox at the point-of-care
-
4
[Review] An updated list of actinomycetoma causative agents and their treatment responses
-
5
[Articles] COVID-19 vaccine effectiveness in people on immunosuppressive therapies: a systematic review and meta-analysis
-
6
[Articles] Investigating the role of a non-synonymous mutation at dhfr codon 50 in maintaining sulphadoxine–pyrimethamine resistance in Plasmodium falciparum: a modelling study
-
7
[Articles] Assessing SARS-CoV-2 immune markers in vaccinated asymptomatic adults after household exposure in Canada (AB-PROTECT): a prospective cohort study
-
8
[Articles] Evaluation of the effect of serotype on pneumococcal conjugate vaccine-induced immunity: an exploratory analysis of the PREVENTING PNEUMO 2 trial
-
9
[Correspondence] Nirsevimab resistance in respiratory syncytial virus-B: virological signal without meaningful clinical impact
-
10
[Correspondence] Necrotising enterocolitis: when microbial metabolism becomes pathogenic
The Lancet Oncology
-
1
[News] Kenya agrees major cuts to cancer drug prices
-
2
[News] Toxic dust around the World Trade Center
-
3
[News] 2026 World Conference on Lung Cancer
-
4
[Articles] Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era
-
5
[News] Increased tobacco production and cigarette imports in Africa
-
6
[Articles] Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial
-
7
[Comment] Why childhood cancer medicines need market shaping led by the Global Platform: toward market transformation
-
8
[Articles] Long-term exposure to wildfire-related PM2·5 and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study
-
9
[Articles] Burden of cancer in Africa, 1990–2023: a systematic analysis from the Global Burden of Disease Study 2023
-
10
[Articles] Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase
The Lancet Planetary Health
-
1
[Articles] Premature mortality and economic losses attributable to landscape fire-related PM2·5 in ten countries and territories: a causal analysis
-
2
[Review] Climate change and animal infectious diseases: a systematic review of emerging evidence
-
3
[Editorial] Future proofing food systems
-
4
[Comment] Urban green spaces: balancing benefits with risks from vector-borne diseases, pesticide exposure, and allergies
-
5
[Articles] Oil and gas well development and coccidioidomycosis risk in Kern County, CA, USA: a case-crossover study
-
6
[Articles] Exploring China’s Clean Air Act and associated cardiovascular disease risk: a prospective, quasi-experimental, and causal inference modelling study
-
7
[Articles] Direct and spillover hospitalisation patterns during climate hazards across regions of different health-system resilience levels in China: a nationwide retrospective analysis
-
8
[Viewpoint] From population to individual: advocating personalised digital tools for heat-health early warning in a changing climate
-
9
[Articles] Impacts of climate-driven yield changes on the affordability of healthy diets: a modelling study
-
10
[Feature] Special Economic Zones, Casinos and the Threat of Zoonotic Diseases
The Lancet Psychiatry
-
1
[Comment] Challenges and implications of enabling community-led mental health initiatives
-
2
[Comment] Open Dialogue after ODDESSI: an odyssey of enthusiasm, expectancy, and evidence
-
3
[Editorial] Sending the right message
-
4
[Corrections] Correction to Lancet Psychiatry 2026; 13: 841–51
-
5
[Corrections] Correction to Lancet Psychiatry 2026; 13: 783–91
-
6
[Insight] The patient declined
-
7
[Comment] Beyond mental health law reform: Argentina and the clinical challenges of implementation
-
8
[Personal View] From prediction to decision: prediction-based decision rules and target trial emulation in ADHD
-
9
[Comment] Mental health law and policy in Argentina: from rights expansion to rollback
-
10
[Comment] Relapse or rebound: the case for personalisation in antipsychotic discontinuation